Xiangting Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiangting Wang has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
Bowen Zhang
Department of Geriatrics, Gerontology Institute of Anhui Province, Centre for Leading Medicine and Advanced Technologies of IHM, Anhui Key Laboratory of Geriatric Immunology and Nutritional Therapy, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
5 shared publicationsXiaolin Liang
Department of Geriatrics, Gerontology Institute of Anhui Province, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
5 shared publicationsHuihui Sun
Department of Geriatrics, Gerontology Institute of Anhui Province, Centre for Leading Medicine and Advanced Technologies of IHM, Anhui Key Laboratory of Geriatric Immunology and Nutritional Therapy, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
4 shared publicationsMeiting Wang
Department of Geriatrics, Gerontology Institute of Anhui Province, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
4 shared publications- Xiaolin Liang
Department of Geriatrics, Gerontology Institute of Anhui Province, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
4 shared publications Fanghong Shao
Department of Geriatrics, Gerontology Institute of Anhui Province, The First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
3 shared publications
Latest Publications
- 24 July 2026
- Published by Springer Nature in Science China Life Sciences
- p. 1-13
TRMT10A maintains lipid homeostasis independently of its tRNA m1G9 methyltransferase activity
- 24 July 2026
- Published by Springer Nature in Science China Life Sciences
- p. 1-13
TRMT10A maintains lipid homeostasis independently of its tRNA m1G9 methyltransferase activity
- Open Access
- 28 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1764106
Multi-omics characterization of RNA modification enzymes identifies NAT10 as a functionally validated prognostic biomarker in hepatocellular carcinoma
Background: RNA modification enzymes (RMEs) are key post-transcriptional regulators that impact RNA stability, translation, and splicing. Dysregulation of RMEs is closely associated with tumor initiation and progression. However, their global regulatory patterns and clinical relevance across cancer types remain incompletely characterized. Methods: We conducted an integrative multi-omics analysis of RME expression, copy number variation (CNV), and clinical outcomes across multiple cancers. Machine learning algorithms were employed to identify tumor-discriminating RME signatures. Single-cell RNA sequencing (scRNA-seq) characterized tumor microenvironmental heterogeneity. A LASSO-derived prognostic model was established and validated in independent cohorts. Drug sensitivity prediction and supportive functional assays (EdU assays, qRT-PCR, immunohistochemistry) were performed for representative RMEs. Results: RMEs were broadly upregulated across cancers and showed strong associations with CNV gains. Machine learning identified 12 RMEs that reliably discriminated tumor from normal tissues. Single-cell transcriptomic analysis showed that 10 of the 12 selected RMEs (DKC1, METTL1, NAT10, TRMT1, RPUSD1, PUS1, WDR4, TRMU, ADAT2, GTPBP3) exhibited higher expression in tumor-infiltrating cells compared with adjacent normal tissues. T-cell subpopulations displayed marked heterogeneity, with ADAT2 preferentially enriched in regulatory T cells. CellChat analysis revealed T cell subsets as key mediators of intercellular communication via multiple immune-related pathways. A 6-gene prognostic model exhibited independent prognostic power and was integrated into a well-calibrated nomogram. Drug-response prediction revealed that high-risk patients exhibited enhanced sensitivity to microtubule-targeting agents and kinase inhibitors, whereas low-risk patients showed preferential response to epigenetic modulators. Importantly, supportive functional assays showed that NAT10 knockdown, validated by qRT-PCR, was associated with reduced proliferative activity in HCC cells as evidenced by EdU assays, and IHC validation further corroborated its overexpression in clinical tumor specimens compared to adjacent normal tissues. Conclusions: This study delineates a CNV-associated landscape of RME dysregulation across cancers and establishes a 12-RME diagnostic signature and a 6-gene prognostic model with robust predictive performance. Single-cell analyses reveal tumor- and cell-type-specific expression patterns of RMEs, while supportive functional data suggest a potential biological relevance of NAT10 in HCC. Collectively, these findings provide an association-based framework for understanding the potential roles of RNA modification programs in cancer progression and clinical stratification.
- 28 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1764106
Open AccessMulti-omics characterization of RNA modification enzymes identifies NAT10 as a functionally validated prognostic biomarker in hepatocellular carcinoma
Background: RNA modification enzymes (RMEs) are key post-transcriptional regulators that impact RNA stability, translation, and splicing. Dysregulation of RMEs is closely associated with tumor initiation and progression. However, their global regulatory patterns and clinical relevance across cancer types remain incompletely characterized. Methods: We conducted an integrative multi-omics analysis of RME expression, copy number variation (CNV), and clinical outcomes across multiple cancers. Machine learning algorithms were employed to identify tumor-discriminating RME signatures. Single-cell RNA sequencing (scRNA-seq) characterized tumor microenvironmental heterogeneity. A LASSO-derived prognostic model was established and validated in independent cohorts. Drug sensitivity prediction and supportive functional assays (EdU assays, qRT-PCR, immunohistochemistry) were performed for representative RMEs. Results: RMEs were broadly upregulated across cancers and showed strong associations with CNV gains. Machine learning identified 12 RMEs that reliably discriminated tumor from normal tissues. Single-cell transcriptomic analysis showed that 10 of the 12 selected RMEs (DKC1, METTL1, NAT10, TRMT1, RPUSD1, PUS1, WDR4, TRMU, ADAT2, GTPBP3) exhibited higher expression in tumor-infiltrating cells compared with adjacent normal tissues. T-cell subpopulations displayed marked heterogeneity, with ADAT2 preferentially enriched in regulatory T cells. CellChat analysis revealed T cell subsets as key mediators of intercellular communication via multiple immune-related pathways. A 6-gene prognostic model exhibited independent prognostic power and was integrated into a well-calibrated nomogram. Drug-response prediction revealed that high-risk patients exhibited enhanced sensitivity to microtubule-targeting agents and kinase inhibitors, whereas low-risk patients showed preferential response to epigenetic modulators. Importantly, supportive functional assays showed that NAT10 knockdown, validated by qRT-PCR, was associated with reduced proliferative activity in HCC cells as evidenced by EdU assays, and IHC validation further corroborated its overexpression in clinical tumor specimens compared to adjacent normal tissues. Conclusions: This study delineates a CNV-associated landscape of RME dysregulation across cancers and establishes a 12-RME diagnostic signature and a 6-gene prognostic model with robust predictive performance. Single-cell analyses reveal tumor- and cell-type-specific expression patterns of RMEs, while supportive functional data suggest a potential biological relevance of NAT10 in HCC. Collectively, these findings provide an association-based framework for understanding the potential roles of RNA modification programs in cancer progression and clinical stratification.
- Open Access
- 28 November 2025
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (12) , 2187-2195
Insights into organelle forming RNAs : Diversity, functions and future perspectives
RNA molecules play diverse and essential roles in cellular processes beyond their well‐known functions in gene expression and regulation. While ribosomal RNAs (rRNAs) have long been recognized as structural components of ribosomes, recent research has highlighted the importance of a distinct group of RNAs which directly compose the structures or organelles in mammalian cells. We refer to these as ‘organelle formation RNAs’. Specifically, the discovery of tubulin‐associated lncRNA ( TubAR ), the first identified cytoskeleton‐forming RNA, has expanded our understanding of RNA functionality; we now recognize ‘organelle formation RNAs’ not only as regulatory molecules but also as direct structural components within cellular subunits. Other ‘organelle formation RNAs’ include paraspeckle‐forming RNAs, nuclear speckle‐forming RNAs, and nucleolus‐forming RNAs. Various RNAs contribute to the formation of distinct cellular structures, while also participating in intricate intermolecular interactions. Understanding these molecules not only uncovers their fundamental roles in cellular physiology but also suggests potential applications in the treatment of related diseases. By examining the latest advancements and methodologies in organelle formation RNA research, this review provides a comprehensive overview of the intricate mechanisms of these RNAs and future directions in the field.
- 28 November 2025
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 8 (12) , 2187-2195
Open AccessInsights into organelle forming RNAs : Diversity, functions and future perspectives
RNA molecules play diverse and essential roles in cellular processes beyond their well‐known functions in gene expression and regulation. While ribosomal RNAs (rRNAs) have long been recognized as structural components of ribosomes, recent research has highlighted the importance of a distinct group of RNAs which directly compose the structures or organelles in mammalian cells. We refer to these as ‘organelle formation RNAs’. Specifically, the discovery of tubulin‐associated lncRNA ( TubAR ), the first identified cytoskeleton‐forming RNA, has expanded our understanding of RNA functionality; we now recognize ‘organelle formation RNAs’ not only as regulatory molecules but also as direct structural components within cellular subunits. Other ‘organelle formation RNAs’ include paraspeckle‐forming RNAs, nuclear speckle‐forming RNAs, and nucleolus‐forming RNAs. Various RNAs contribute to the formation of distinct cellular structures, while also participating in intricate intermolecular interactions. Understanding these molecules not only uncovers their fundamental roles in cellular physiology but also suggests potential applications in the treatment of related diseases. By examining the latest advancements and methodologies in organelle formation RNA research, this review provides a comprehensive overview of the intricate mechanisms of these RNAs and future directions in the field.
- Open Access
- 27 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1713
Characterizing and decoding ultraconserved regions uncovers their regulatory significance in human brain development and disorders
Ultraconserved regions (UCRs) represent genomic elements with perfect sequence conservation across humans, rats, and mice. Though evolutionarily significant, most UCRs’ functions remain elusive. Here, by leveraging current reference genomes from 34 species spanning diverse taxonomic groups, we refine the annotation, trace the evolutionary origins, and compile an updated catalog of UCRs. The updated UCRs are mostly 200-400 base pairs long, with lower GC content and SNP density but more deleterious mutations. They first emerge in fish, growing more abundant in vertebrates. Guided by genomic context and functional analyses, we classified them into three categories: type I (within protein-coding genes) mainly encodes brain development splicing regulators; type II (within non-coding genes) associates with lncRNAs linked to brain malignancies; type III (intergenic, 46% overlapping enhancer-like elements) regulates brain development genes. Our findings underscore UCRs’ critical roles in human brain development and disorders, offering a framework for investigating their biological significance.
- 27 November 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1713
Open AccessCharacterizing and decoding ultraconserved regions uncovers their regulatory significance in human brain development and disorders
Ultraconserved regions (UCRs) represent genomic elements with perfect sequence conservation across humans, rats, and mice. Though evolutionarily significant, most UCRs’ functions remain elusive. Here, by leveraging current reference genomes from 34 species spanning diverse taxonomic groups, we refine the annotation, trace the evolutionary origins, and compile an updated catalog of UCRs. The updated UCRs are mostly 200-400 base pairs long, with lower GC content and SNP density but more deleterious mutations. They first emerge in fish, growing more abundant in vertebrates. Guided by genomic context and functional analyses, we classified them into three categories: type I (within protein-coding genes) mainly encodes brain development splicing regulators; type II (within non-coding genes) associates with lncRNAs linked to brain malignancies; type III (intergenic, 46% overlapping enhancer-like elements) regulates brain development genes. Our findings underscore UCRs’ critical roles in human brain development and disorders, offering a framework for investigating their biological significance.
- Open Access
- 4 June 2025
- Published by Springer Nature in Cell Regeneration
- Vol. 14 (1) , 1-13
Alternative splicing in stem cells and development: research progress and emerging technologies
Alternative splicing is a key regulatory mechanism that generates transcriptomic diversity by selectively splicing pre-RNA molecules in different ways, leading to the production of multiple RNA isoforms from a single gene. This process is crucial for the fine-tuning of gene expression and is tightly regulated during various biological processes. Recent studies have highlighted how alternative splicing contributes to stem cells self-renewal and differentiation, as well as how dysregulation of splicing factors can impact stem cells behavior and lead to developmental abnormalities or diseases. This review summarizes the current understanding of alternative splicing in stem cells and development, focusing on the molecular mechanisms that govern alternative splicing regulation, the role of splicing factors, and the impact of splicing isoforms on stem cell fate determination and developmental processes. We also discuss emerging technologies, such as CRISPR/Cas-based tools, single-cell long-read RNA sequencing, imaging technologies and 3D culture systems, which are advancing our ability to study alternative splicing in vitro and in vivo. Overall, this field is rapidly evolving, revealing new insights into how alternative splicing shapes the molecular landscape and functions of stem cells and developmental processes.
- 4 June 2025
- Published by Springer Nature in Cell Regeneration
- Vol. 14 (1) , 1-13
Open AccessAlternative splicing in stem cells and development: research progress and emerging technologies
Alternative splicing is a key regulatory mechanism that generates transcriptomic diversity by selectively splicing pre-RNA molecules in different ways, leading to the production of multiple RNA isoforms from a single gene. This process is crucial for the fine-tuning of gene expression and is tightly regulated during various biological processes. Recent studies have highlighted how alternative splicing contributes to stem cells self-renewal and differentiation, as well as how dysregulation of splicing factors can impact stem cells behavior and lead to developmental abnormalities or diseases. This review summarizes the current understanding of alternative splicing in stem cells and development, focusing on the molecular mechanisms that govern alternative splicing regulation, the role of splicing factors, and the impact of splicing isoforms on stem cell fate determination and developmental processes. We also discuss emerging technologies, such as CRISPR/Cas-based tools, single-cell long-read RNA sequencing, imaging technologies and 3D culture systems, which are advancing our ability to study alternative splicing in vitro and in vivo. Overall, this field is rapidly evolving, revealing new insights into how alternative splicing shapes the molecular landscape and functions of stem cells and developmental processes.
- Open Access
- 28 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (5) , 1414-1441
Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis
MTOR plays a pivotal role in cancer growth control upon amino acid response. Recently, CDK inhibitor P27KIP1 has been reported as a noncanonical inhibitor of mTOR signaling in MEFs, via unclear mechanisms. Here, we find that P27KIP1 degradation via E3 ligase TRIM21 is inhibited by human micropeptide hSPAR through its C-terminus (hSPAR-C), causing P27KIP1’s cytoplasmic accumulation in breast cancer cells. Furthermore, hSPAR/hSPAR-C also serves as an inhibitor of glutamine transporter SLC38A2 expression and thereby decreases the cellular glutamine levels specifically in cancer cells. The resultant glutamine deprivation sequentially triggers translocation of cytoplasmic P27KIP1 to lysosomes, where P27KIP1 disrupts the Ragulator complex and suppresses mTORC1 assembly. Administration of hSPAR or hSPAR-C significantly impedes breast cancer cell proliferation and tumor growth in xenograft models. These findings define hSPAR as an intrinsic control factor for cellular glutamine levels and as a novel tumor suppressor inhibiting mTORC1 assembly.
- 28 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (5) , 1414-1441
Open AccessMicropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis
MTOR plays a pivotal role in cancer growth control upon amino acid response. Recently, CDK inhibitor P27KIP1 has been reported as a noncanonical inhibitor of mTOR signaling in MEFs, via unclear mechanisms. Here, we find that P27KIP1 degradation via E3 ligase TRIM21 is inhibited by human micropeptide hSPAR through its C-terminus (hSPAR-C), causing P27KIP1’s cytoplasmic accumulation in breast cancer cells. Furthermore, hSPAR/hSPAR-C also serves as an inhibitor of glutamine transporter SLC38A2 expression and thereby decreases the cellular glutamine levels specifically in cancer cells. The resultant glutamine deprivation sequentially triggers translocation of cytoplasmic P27KIP1 to lysosomes, where P27KIP1 disrupts the Ragulator complex and suppresses mTORC1 assembly. Administration of hSPAR or hSPAR-C significantly impedes breast cancer cell proliferation and tumor growth in xenograft models. These findings define hSPAR as an intrinsic control factor for cellular glutamine levels and as a novel tumor suppressor inhibiting mTORC1 assembly.
- Open Access
- 27 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
DEAD-box RNA helicase 10 is required for 18S rRNA maturation by controlling the release of U3 snoRNA from pre-rRNA in embryonic stem cells
Ribosome biogenesis plays a pivotal role in maintaining stem cell homeostasis, yet the precise regulatory mechanisms governing this process in mouse embryonic stem cells (mESCs) remain largely unknown. In this investigation, we ascertain that DEAD-box RNA helicase 10 (DDX10) is indispensable for upholding cellular homeostasis and the viability of mESCs. Positioned predominantly at the nucleolar dense fibrillar component (DFC) and granular component (GC), DDX10 predominantly binds to 45S ribosomal RNA (rRNA) and orchestrates ribosome biogenesis. Degradation of DDX10 prevents the release of U3 snoRNA from pre-rRNA, leading to perturbed pre-rRNA processing and compromised maturation of the 18S rRNA, thereby disrupting the biogenesis of the small ribosomal subunit. Moreover, DDX10 participates in the process of liquid-liquid phase separation (LLPS), which is necessary for efficient ribosome biogenesis. Notably, the NUP98-DDX10 fusion associated with acute myelocytic leukemia (AML) alters the cellular localization of DDX10 and results in loss of ability to regulate pre-rRNA processing. Collectively, this study reveals the critical role of DDX10 as a pivotal regulator of ribosome biogenesis in mESCs.
- 27 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessDEAD-box RNA helicase 10 is required for 18S rRNA maturation by controlling the release of U3 snoRNA from pre-rRNA in embryonic stem cells
Ribosome biogenesis plays a pivotal role in maintaining stem cell homeostasis, yet the precise regulatory mechanisms governing this process in mouse embryonic stem cells (mESCs) remain largely unknown. In this investigation, we ascertain that DEAD-box RNA helicase 10 (DDX10) is indispensable for upholding cellular homeostasis and the viability of mESCs. Positioned predominantly at the nucleolar dense fibrillar component (DFC) and granular component (GC), DDX10 predominantly binds to 45S ribosomal RNA (rRNA) and orchestrates ribosome biogenesis. Degradation of DDX10 prevents the release of U3 snoRNA from pre-rRNA, leading to perturbed pre-rRNA processing and compromised maturation of the 18S rRNA, thereby disrupting the biogenesis of the small ribosomal subunit. Moreover, DDX10 participates in the process of liquid-liquid phase separation (LLPS), which is necessary for efficient ribosome biogenesis. Notably, the NUP98-DDX10 fusion associated with acute myelocytic leukemia (AML) alters the cellular localization of DDX10 and results in loss of ability to regulate pre-rRNA processing. Collectively, this study reveals the critical role of DDX10 as a pivotal regulator of ribosome biogenesis in mESCs.
- Open Access
- 21 May 2024
- Published by Springer Nature in Cell Discovery
- Vol. 10 (1) , 1-19
LncRNA TubAR complexes with TUBB4A and TUBA1A to promote microtubule assembly and maintain myelination
A long-standing hypothesis proposes that certain RNA(s) must exhibit structural roles in microtubule assembly. Here, we identify a long noncoding RNA (TubAR) that is highly expressed in cerebellum and forms RNA–protein complex with TUBB4A and TUBA1A, two tubulins clinically linked to cerebellar and myelination defects. TubAR knockdown in mouse cerebellum causes loss of oligodendrocytes and Purkinje cells, demyelination, and decreased locomotor activity. Biochemically, we establish the roles of TubAR in promoting TUBB4A–TUBA1A heterodimer formation and microtubule assembly. Intriguingly, different from the hypomyelination-causing mutations, the non-hypomyelination-causing mutation TUBB4A-R2G confers gain-of-function for an RNA-independent interaction with TUBA1A. Experimental use of R2G/A mutations restores TUBB4A–TUBA1A heterodimer formation, and rescues the neuronal cell death phenotype caused by TubAR knockdown. Together, we uncover TubAR as the long-elusive structural RNA for microtubule assembly and demonstrate how TubAR mediates microtubule assembly specifically from αβ-tubulin heterodimers, which is crucial for maintenance of cerebellar myelination and activity.
- 21 May 2024
- Published by Springer Nature in Cell Discovery
- Vol. 10 (1) , 1-19
Open AccessLncRNA TubAR complexes with TUBB4A and TUBA1A to promote microtubule assembly and maintain myelination
A long-standing hypothesis proposes that certain RNA(s) must exhibit structural roles in microtubule assembly. Here, we identify a long noncoding RNA (TubAR) that is highly expressed in cerebellum and forms RNA–protein complex with TUBB4A and TUBA1A, two tubulins clinically linked to cerebellar and myelination defects. TubAR knockdown in mouse cerebellum causes loss of oligodendrocytes and Purkinje cells, demyelination, and decreased locomotor activity. Biochemically, we establish the roles of TubAR in promoting TUBB4A–TUBA1A heterodimer formation and microtubule assembly. Intriguingly, different from the hypomyelination-causing mutations, the non-hypomyelination-causing mutation TUBB4A-R2G confers gain-of-function for an RNA-independent interaction with TUBA1A. Experimental use of R2G/A mutations restores TUBB4A–TUBA1A heterodimer formation, and rescues the neuronal cell death phenotype caused by TubAR knockdown. Together, we uncover TubAR as the long-elusive structural RNA for microtubule assembly and demonstrate how TubAR mediates microtubule assembly specifically from αβ-tubulin heterodimers, which is crucial for maintenance of cerebellar myelination and activity.
- 19 March 2024
- Published by Springer Nature in Human Genetics
- Vol. 143 (3) , 385-399
Genome-wide analyses reveal the regulatory roles of DNA methylation-regulated alternative promoter transcripts in breast cancer
A certain proportion of genes are regulated by multiple, distinct promoters, revealing a dynamic landscape of the cancer transcriptome. However, the contribution of alternative promoters (APs) in breast cancer (BRCA) remains largely unexplored. Here, we identified 3654 genes with multiple promoters in BRCA patients, and 53 of them could generate distinct AP transcripts that are dysregulated and prognosis-related in BRCA, namely prognosis-related dysregulated AP (prdeAP) transcripts. Interestingly, when we searched for the genomic signatures of these prdeAP genes, we found that the promoter regions of 92% of the prdeAP genes were enriched with abundant DNA methylation signals. Through further bioinformatic analysis and experimental validation, we showed that AP selections of TANK, UNKL, CCL28, and MAP1LC3A were regulated by DNA methylation upon their corresponding promoter regions. Functionally, by overexpressing AP variants of TANK, we found that TANK|55731 could dramatically suppress MDA-MB-231 cell proliferation and migration. Meanwhile, pan-cancer survival analyses suggested that AP variants of TANK provided more accurate prognostic predictive ability than TANK gene in a variety of tumor types, including BRCA. Together, by uncovering the DNA methylation-regulated AP transcripts with tumor prognostic features, our work revealed a novel layer of regulators in BRCA progression and provided potential targets that served as effective biomarkers for anti-BRCA treatment.
- 19 March 2024
- Published by Springer Nature in Human Genetics
- Vol. 143 (3) , 385-399
Genome-wide analyses reveal the regulatory roles of DNA methylation-regulated alternative promoter transcripts in breast cancer
A certain proportion of genes are regulated by multiple, distinct promoters, revealing a dynamic landscape of the cancer transcriptome. However, the contribution of alternative promoters (APs) in breast cancer (BRCA) remains largely unexplored. Here, we identified 3654 genes with multiple promoters in BRCA patients, and 53 of them could generate distinct AP transcripts that are dysregulated and prognosis-related in BRCA, namely prognosis-related dysregulated AP (prdeAP) transcripts. Interestingly, when we searched for the genomic signatures of these prdeAP genes, we found that the promoter regions of 92% of the prdeAP genes were enriched with abundant DNA methylation signals. Through further bioinformatic analysis and experimental validation, we showed that AP selections of TANK, UNKL, CCL28, and MAP1LC3A were regulated by DNA methylation upon their corresponding promoter regions. Functionally, by overexpressing AP variants of TANK, we found that TANK|55731 could dramatically suppress MDA-MB-231 cell proliferation and migration. Meanwhile, pan-cancer survival analyses suggested that AP variants of TANK provided more accurate prognostic predictive ability than TANK gene in a variety of tumor types, including BRCA. Together, by uncovering the DNA methylation-regulated AP transcripts with tumor prognostic features, our work revealed a novel layer of regulators in BRCA progression and provided potential targets that served as effective biomarkers for anti-BRCA treatment.
- Open Access
- 25 December 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 6 (6) , 505-507
LncRNAs: Current understanding, future directions, and challenges
- 25 December 2023
- Published by Wiley in Animal Models and Experimental Medicine
- Vol. 6 (6) , 505-507
Open AccessLncRNAs: Current understanding, future directions, and challenges